Journals / Clinical and Experimental Health Sciences / 2011 / Cilt: 1 - Sayı: 3

Antimicrobial resistance patterns of Clostridium difficile strains isolated from Marmara University Hospital

Marmara Üniversitesi Hastanesi’nde izole edilen Clostridium difficile kökenlerinin antibiyotiklere direnç durumu

Pages
162–165
Publication Date
2014-01-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our findings determine the current antibiotic susceptibility patterns of the Clostridium difficile isolates in our region and also in Turkey, where clinical laboratories do not routinely perform culture and susceptibility testing of the organism.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study was designed to investigate antimicrobial resistance patterns of toxigenic Clostridium difficile strains isolated from Marmara University Hospital.
📊
Key Findings & Data:Methods: The stool specimens ordered for detection of Clostridium difficile toxin at the Microbiology Laboratory, between April 2008 and January 2010 were cultured anaerobically.
💡
Conclusion & Impact:Our findings determine the current antibiotic susceptibility patterns of the Clostridium difficile isolates in our region and also in Turkey, where clinical laboratories do not routinely perform culture and susceptibility testing of the organism.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Clostridium difficile · antibiyotiklere direnç · vankomisin

Abstract

Objective: This study was designed to investigate antimicrobial resistance patterns of toxigenic Clostridium difficile strains isolated from Marmara University Hospital. Methods: The stool specimens ordered for detection of Clostridium difficile toxin at the Microbiology Laboratory, between April 2008 and January 2010 were cultured anaerobically. The antimicrobial susceptibility of the isolated 50 toxigenic Clostridium difficile strains was determined using the agar dilution protocol in the CLSI guidelines (M11-A7). The investigated antibiotics were metronidazole, vancomycin, meropenem clindamycin, and ampicillin. Breakpoints of susceptibility for each drug were considered according to the levels listed by the CLSI, intermediate strains evaluated as resistant ones. Results: All isolates were sensitive to metronidazole, vancomycin and meropenem. Resistance rates to clindamycin and ampicillin were 62% and 68%, respectively. Conclusion: For now there seems to be no resistance risk for metronidazole and vancomycin, the two agents commonly used to treat Clostridium difficile-associated diarrhea. Our findings determine the current antibiotic susceptibility patterns of the Clostridium difficile isolates in our region and also in Turkey, where clinical laboratories do not routinely perform culture and susceptibility testing of the organism.

Özet

Amaç: Bu çalışmada Marmara Üniversitesi Hastanesi’nde izole edilen toksijenik Clostridium difficile kökenlerinin antibiyotiklere direnç durumunun araştırılması amaçlanmıştır. Yöntemler: Mikrobiyoloji Laboratuvarına Nisan 2008 - Ocak 2010 tarihleri arasında, Clostridium difficile toksini bakılması isteğiyle gönderilen dışkılardan anaerop kültür yapılmış, izole edilen 50 toksijenik kökenin, CLSI’nın önerdiği (M11-A7) agarda dilüsyon yöntemi ile antibiyotik duyarlılıkları çalışılmıştır Antibiyotiklerden metronidazol, vankomisin, meropenem, klindamisin ve ampisilin seçilmiştir. Orta düzeyde dirençli olanlar da dirençliler arasında gösterilmiştir. Bulgular: Tüm kökenler metronidazol, vankomisin ve meropeneme duyarlı bulunmuştur. Kökenlerin %62’sinde klindamisine, %68’inde ise ampisiline direnç saptanmıştır. Sonuç: Elde ettiğimiz sonuçlara göre hastanemizde şu ana kadar, Clostridium difficile’ye bağlı ishal tedavisinde en fazla kullanılan antibiyotiklerden metronidazol ve vankomisine karşı bir direnç tehlikesi görülmemektedir. Ayrıca, klinik mikrobiyoloji laboratuvarlarında rutinde kültürü ve antibiyotik duyarlılığı yapılmayan Clostridium difficile ile ilgili verilerimiz, ülkemizde yapılacak diğer çalışmalara da ışık tutacaktır.

🔖

Cite This Article

Ülger, N. T., İlki, A., Akgül, Ö., Soyletir, G. (2014). Antimicrobial resistance patterns of Clostridium difficile strains isolated from Marmara University Hospital. Clinical and Experimental Health Sciences, Cilt: 1 - Sayı: 3, 162–165. https://ajindex.com/articles/481908

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Bartlett J.G. Antibiotic associated diarrhea. N Engl J Med. 2002; 346:334-339.
  2. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile- related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2007; 13: 1417-1419.
  3. Kuijper EJ, Coignard B, Tüll P, ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006; 12(Suppl 6): 2-18.
  4. Gilca R, Hubert B, Fortin E, Gaulin C, Dionne M. Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Quebec, Canada, 1998- 2006. Infect Control Hosp Epidemiol. 2010; 31: 939-947. O’Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009;136: 1913–1924. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, Approved Standards-7th Edition, M11-A7, CLSI, Pennsylvania, USA, 2007.
  5. Leroi M.J, Siarakas S, Gottlieb TE. Test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid. Eur J Clin Microbiol Infect Dis. 2002;21: 72–74.
  6. Hecht D.W, Galang M.A, Sambol S.P, Osmolski J.R, Johnson S, Gerding D.N. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51: 2716–2719.
  7. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I and European Study Group on Clostridium difficile (ESGCD). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect. 2007;13: 1048–1057. Dworczyński A, Sokół B, Meisel-Mikołajczyk F. Antibiotic resistance of Clostridium difficile isolates. Cytobios. 1991;65.149-153.
  8. Brazier J. S, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother. 2001; 48:741–742.
  9. Drummond LJ, McCoubrey J, Smith D.G, Starr JM, Poxton IR. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol. 2003; 52: 259–263. Peláez T, Cercenado E, Alcalá L, Marín M, Martín-Lóp